Voyager shares take a hit as FDA slaps a hold on the IND for Huntington's gene therapy — their #2 play in the pipeline
A little more than a year after Sanofi handed back rights to Voyager’s $VYGR gene therapy program for Huntington’s in exchange for a cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
